Ardelyx, Inc. discovers, develops, and commercializes non-systemic small molecule therapeutics for the gastrointestinal tract to treat cardio-renal and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that a...
34175 Ardenwood Boulevard
Fremont, CA 94555
Founded in 2007
Ardelyx, Inc. Announces Retirement of Dominique Charmot as Chief Scientific Officer, Effective from December 23, 2014
Sep 5 14
Ardelyx, Inc. announced that Dominique Charmot, Ph.D., the company's Chief Scientific Officer, has announced his retirement from Ardelyx, effective December 23, 2014. Dr. Charmot cited personal reasons for his departure, including his desire to spend more time with his family.
Ardelyx, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2014
Aug 7 14
Ardelyx, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of $9,137,000, income from operations of $2,751,000, income before provision for income taxes of $3,753,000, net income and comprehensive income of $3,753,000 or $0.18 per diluted share compared to the total revenue of $7,291,000, loss from operations of $851,000, loss before provision for income taxes of $855,000, net loss and comprehensive loss of $891,000 or $0.81 per diluted share for the same quarter a year ago.
For the six months period, the company reported total revenue of $17,687,000, income from operations of $2,287,000, income before provision for income taxes of $682,000, net income and comprehensive income of $682,000 compared to the total revenue of $13,847,000, loss from operations of $1,261,000, loss before provision for income taxes of $1,290,000, net loss and comprehensive loss of $1,361,000 or $1.27 per diluted share for the same period a year ago.
Ardelyx, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 02:30 PM
Jul 24 14
Ardelyx, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 02:30 PM. Venue: Le Parker Meridien, New York, New York, United States. Speakers: Michael G. Raab, Chief Executive Officer, President and Director.